Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Godfrey

Showing results (51-60 of 103) with videos related to

Pageof 11
Sort By:
AIDS (London, England)|July 25, 2022
Enabling timely HIV postexposure prophylaxis access in sub-Saharan AfricaAndrew N Phillips, Euphemia Sibanda, Kenly Sikwese, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2013
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabineKimberly Y Smith, Camlin Tierney, Katie Mollan, et al.
Journal of the International AIDS Society|September 29, 2022
Non-communicable diseases by age strata in people living with and without HIV in four African countriesDavid Chang, Allahna L Esber, Nicole F Dear, et al.
JAMA|August 15, 2006
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionSusan Swindells, A Gregory DiRienzo, Timothy Wilkin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 31, 2010
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patientsTimothy J Wilkin, Zhaohui Su, Amy Krambrink, et al.
The Journal of Infectious Diseases|September 21, 2025
Advancing Infection Prevention and Control in the United States PEPFAR ProgramsDanica J Gomes, Elizabeth A Bancroft, Ismail Lawal, et al.
The Lancet. Digital Health|September 19, 2019
Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trialRobert Gross, Justin Ritz, Michael D Hughes, et al.
The New England Journal of Medicine|July 22, 2010
Early versus standard antiretroviral therapy for HIV-infected adults in HaitiPatrice Severe, Marc Antoine Jean Juste, Alex Ambroise, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2014
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected womenErna Milunka Kojic, Minhee Kang, Michelle S Cespedes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 19, 2017
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mLBabafemi O Taiwo, Lu Zheng, Andrei Stefanescu, et al.
Pageof 11

Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
AIDS (London, England)|July 25, 2022
Enabling timely HIV postexposure prophylaxis access in sub-Saharan AfricaAndrew N Phillips, Euphemia Sibanda, Kenly Sikwese, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2013
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabineKimberly Y Smith, Camlin Tierney, Katie Mollan, et al.
Journal of the International AIDS Society|September 29, 2022
Non-communicable diseases by age strata in people living with and without HIV in four African countriesDavid Chang, Allahna L Esber, Nicole F Dear, et al.
JAMA|August 15, 2006
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionSusan Swindells, A Gregory DiRienzo, Timothy Wilkin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 31, 2010
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patientsTimothy J Wilkin, Zhaohui Su, Amy Krambrink, et al.
The Journal of Infectious Diseases|September 21, 2025
Advancing Infection Prevention and Control in the United States PEPFAR ProgramsDanica J Gomes, Elizabeth A Bancroft, Ismail Lawal, et al.
The Lancet. Digital Health|September 19, 2019
Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trialRobert Gross, Justin Ritz, Michael D Hughes, et al.
The New England Journal of Medicine|July 22, 2010
Early versus standard antiretroviral therapy for HIV-infected adults in HaitiPatrice Severe, Marc Antoine Jean Juste, Alex Ambroise, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2014
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected womenErna Milunka Kojic, Minhee Kang, Michelle S Cespedes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 19, 2017
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mLBabafemi O Taiwo, Lu Zheng, Andrei Stefanescu, et al.
Pageof 11